Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Terbinafine vs Hydrocortisone with Oral Itraconazole for Seborrheic Dermatitis
NCT07906886Phase 4Completed
- Sponsor
- Can Tho University of Medicine and Pharmacy
- Start
- Jul 2025
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 4, open-label trial of Terbinafine subungual gel in seborrheic dermatitis (SD) (2 arms), sponsored by Can Tho University of Medicine and Pharmacy. Primary endpoint: Seborrheic Dermatitis Area and Severity Index at 2 weeks. Started Jul 2025; status: completed.
02
Drugs
Terbinafine subungual gel
03
Conditions
seborrheic dermatitis (SD)
Beyond the preview
Go deeper on NCT07906886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07906886.